<DOC>
	<DOC>NCT01266512</DOC>
	<brief_summary>Primary Objective: - Response rate (by contrast CT scan) Secondary Objectives: - Progression-free survival (PFS) - Overall survival (OS)</brief_summary>
	<brief_title>Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) &amp; Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer</brief_title>
	<detailed_description>The duration of the study for each patient will include an up to 6-week screening phase, 12 weeks treatment phase (including a resting period of 2 weeks) followed by a long-term follow-up.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criteria: Pathologically proven locally advanced, inoperable, confirmed by PET scan (thorax/ upper abdomen) to be International stage III (2009) NSCLC and without multifocal tumours in the lung Disease volume encompassible within a tolerable Planning Target Volume treated to 66 Gy FEV1 (Force Expiratory Volume in 1 Second) &gt;1000 ml Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count (ANC) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Total bilirubin ≥ 1.5 times the upper limit of normal ALT (Alanine Aminotransferase) and AST (Aspartate transaminase) ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for patients with liver derangement) ECOG (Eastern Cooperative Oncology Group) PS 01 Exclusion criteria: Previous treatment with chest radiotherapy, chemotherapy or molecularly targeted agents Inadequate lung function (Exercise tolerance less than 1 FOS/Fight of stairs, FEV1 &lt; 1 L/sec, or raised pCO2) History of hypersensitivity or contraindication to the study drugs or premedications or products formulated in polysorbate 80 Pregnant or breastfeeding women, or women with childbearing potential who are not following an effective method of contraception and/or who are unwilling or unable to be tested for pregnancy (either by serum or urine pregnancy test before study entry Participation in a clinical trial with any investigational drug used and within 30 days prior to study entry The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>